Bretton Capital Management, an investment management company, released “Bretton Fund” fourth quarter 2024 investor letter. A copy of the letter can be downloaded here. The market is experiencing a period of high returns, with two consecutive years of around 25% returns and 15 years of mid-teens returns, prompting investors to be cautious. The average stock market return is around 9-10% per year, historically, based on corporate earnings growth and dividends and buybacks. The 20 companies the fund owns are well-positioned and expected to perform well. Against this backdrop, in the fourth quarter, the fund returned -0.98% compared to 2.41% return for the S&P 500. In addition, you can check the fund’s top 5 holdings to determine its best picks for 2024.
In its fourth quarter 2024 investor letter, Bretton Fund emphasized stocks such as Revvity, Inc. (NYSE:RVTY). Revvity, Inc. (NYSE:RVTY) offers health sciences solutions, technologies, and services. The one-month return of Revvity, Inc. (NYSE:RVTY) was -5.18%, and its shares gained 9.56% of their value over the last 52 weeks. On February 14, 2025, Revvity, Inc. (NYSE:RVTY) stock closed at $112.26 per share with a market capitalization of $13.662 billion.
Bretton Fund stated the following regarding Revvity, Inc. (NYSE:RVTY) in its Q4 2024 investor letter:
“Revvity, Inc. (NYSE:RVTY)—the former PerkinElmer—has been on a roller coaster ride the last few years. It generated windfall prohts from its testing business during Covid, disposed of its food testing business (along with its corporate name), plowed all that money into cutting-edge diagnostics and reagents acquisitions, and watched as the entire healthcare industry went into a post-Covid hangover.
After all the comings and goings, its portfolio has simplihed a bit. Revvity owns two major businesses: a reagent business, selling a catalog of 75,000 products to academic and corporate medical researchers, and an immunodiagnostics business, selling machines and consumables to diagnose autoimmune diseases, infectious diseases, and allergies. There are also two smaller businesses: a software company for lab workers who use their reagents, and the global leader in newborn baby screening. Revvity gained 2.4% last year and trades for about 23x earnings.”
A scientist peering into a microscope, exploring innovative diagnostics techniques.
Revvity, Inc. (NYSE:RVTY) is not on our list of 30 Most Popular Stocks Among Hedge Funds. As per our database, 27 hedge fund portfolios held Revvity, Inc. (NYSE:RVTY) at the end of the third quarter which was 22 in the previous quarter. In the fourth quarter, Revvity, Inc. (NYSE:RVTY) achieved 6% organic growth, generating $730 million in adjusted revenues and for the full year, the company generated $2.76 billion of total adjusted revenue. While we acknowledge the potential of Revvity, Inc. (NYSE:RVTY) as an investment, our conviction lies in the belief that AI stocks hold greater promise for delivering higher returns, and doing so within a shorter timeframe. If you are looking for an AI stock that is as promising as NVIDIA but that trades at less than 5 times its earnings, check out our report about the cheapest AI stock.
In addition, please check out our hedge fund investor letters Q4 2024 page for more investor letters from hedge funds and other leading investors.
READ NEXT: Michael Burry Is Selling These Stocks and A New Dawn Is Coming to US Stocks.
Disclosure: None. This article is originally published at Insider Monkey.
